Answers are grounded in this paper and cite their sources.
Antiplatelet drugs and various systemic conditions are common causes of acquired platelet dysfunction, which can be diagnosed via platelet function testing and managed with targeted therapies.
A qualitative abnormality of platelet function should be considered in patients with mucocutaneous bleeding in the absence of thrombocytopenia or von Willebrand disease. Antiplatelet drugs are the most common cause of acquired platelet disorders leading to bleeding. Uremia, hepatic cirrhosis, myeloma and related disorders, polycythemia vera, essential thrombocythemia, and cardiopulmonary bypass have long been recognized as clinical situations in which platelet dysfunction may contribute to bleeding. When an acquired platelet disorder is suspected, it is useful to examine platelet function by measuring the bleeding time, examining platelet-dependent closure time in a platelet function analyzer and performing platelet aggregometry. When a specific acquired platelet disorder is diagnosed, many treatment options are available including controlling the underlying disease, giving platelet transfusions and administering a hemostatic drug.
No takes yet. Share an insight, caveat, or question.
Hassan et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: